18414037	207	Palomero T	The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia.	Cell cycle	2008	65
25541152	207	Musilova K	MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.	Leukemia	2015	32
18451166	238	McDermott U	Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.	Cancer research	2008	119
18990089	238	Carén H	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.	The Biochemical journal	2008	61
19671850	238	Rodig SJ	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.	Clinical cancer research 	2009	141
20418096	238	Sasaki T	The biology and treatment of EML4-ALK non-small cell lung cancer.	European journal of cancer	2010	101
20979469	238	Kwak EL	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.	The New England journal of medicine	2010	1033
20979472	238	Butrynski JE	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.	The New England journal of medicine	2010	140
20979473	238	Choi YL	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	The New England journal of medicine	2010	271
21030459	238	Sasaki T	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.	Cancer research	2010	98
21156280	238	Gerber DE	ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.	Cancer cell	2010	65
21336183	238	Camidge DR	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.	Journal of thoracic oncology 	2011	61
21502504	238	Katayama R	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.	Proceedings of the National Academy of Sciences of the United States of America	2011	147
21575866	238	Sakamoto H	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.	Cancer cell	2011	114
21596819	238	Murugan AK	Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.	Cancer research	2011	42
21623265	238	Ou SH	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	Journal of thoracic oncology 	2011	96
21642865	238	Lee JO	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.	Journal of thoracic oncology 	2011	38
21933749	238	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	199
22034911	238	Zhang S	Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.	Chemical biology and drug design	2011	41
22071784	238	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	40
22129856	238	Paik JH	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.	Lung cancer	2012	34
22184391	238	van Gaal JC	Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.	Journal of clinical oncology 	2012	32
22589483	238	Matthay KK	Promising therapeutic targets in neuroblastoma.	Clinical cancer research 	2012	41
22735679	238	Ilie M	ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.	Annals of oncology 	2012	37
23344087	238	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	38
23401436	238	Shaw AT	ALK in lung cancer: past, present, and future.	Journal of clinical oncology 	2013	77
23598171	238	Mossé YP	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.	The Lancet. Oncology	2013	100
23724914	238	Awad MM	Acquired resistance to crizotinib from a mutation in CD74-ROS1.	The New England journal of medicine	2013	53
24060861	238	Hallberg B	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.	Nature reviews. Cancer	2013	82
24675041	238	Friboulet L	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	Cancer discovery	2014	128
24736079	238	Ignatius Ou SH	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.	Journal of thoracic oncology 	2014	33
24819116	238	Johnson TW	Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo4,3-h2,5,11-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.	Journal of medicinal chemistry	2014	38
25228534	238	Katayama R	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research 	2014	45
25724526	238	Gainor JF	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.	Clinical cancer research 	2015	25
26554404	238	Infarinato NR	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.	Cancer discovery	2016	14
26698910	238	Shaw AT	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.	The New England journal of medicine	2016	42
2250705	596	Hockenbery D	Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.	Nature	1990	495
3874430	596	Tsujimoto Y	Involvement of the bcl-2 gene in human follicular lymphoma.	Science	1985	237
22929980	596	Visco C	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.	Haematologica	2013	28
23471820	596	Sanda T	TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.	Cancer discovery	2013	30
22113614	604	Duan S	FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.	Nature	2012	69
21663470	673	Tiacci E	BRAF mutations in hairy-cell leukemia.	The New England journal of medicine	2011	157
25150798	695	Burger JA	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.	The Lancet. Oncology	2014	56
25189416	695	Cheng S	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	Leukemia	2015	20
26641137	695	Byrd JC	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.	The New England journal of medicine	2016	43
23352661	861	Wilkinson AC	RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.	Cell reports	2013	35
25082755	1019	Chiron D	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.	Cancer discovery	2014	33
8118801	1026	el-Deiry WS	WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.	Cancer research	1994	376
26551667	1027	da Silva Almeida AC	The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.	Nature genetics	2015	27
10541553	1029	Schmitt CA	INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.	Genes and development	1999	135
15608680	1029	Tagawa H	Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.	Oncogene	2005	85
17890455	1029	Kawamata N	Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.	Blood	2008	57
18688286	1029	Howe SJ	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.	The Journal of clinical investigation	2008	321
21248843	1029	Notta F	Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.	Nature	2011	154
24127483	1029	Fabbri G	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	The Journal of experimental medicine	2013	26
24957142	1029	Moorman AV	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	Blood	2014	24
26551670	1029	Wang L	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	Nature genetics	2015	24
19075268	1050	Koschmieder S	Dysregulation of the C/EBPalpha differentiation pathway in human cancer.	Journal of clinical oncology 	2009	45
21390130	1387	Mullighan CG	CREBBP mutations in relapsed acute lymphoblastic leukaemia.	Nature	2011	162
24662245	1387	Mar BG	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.	Nature communications	2014	35
25713363	1387	Green MR	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	Proceedings of the National Academy of Sciences of the United States of America	2015	33
22665537	1649	Green TM	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	79
24943107	1649	Oki Y	Double hit lymphoma: the MD Anderson Cancer Center clinical experience.	British journal of haematology	2014	26
22216861	1788	Couronné L	TET2 and DNMT3A mutations in human T-cell lymphoma.	The New England journal of medicine	2012	60
23341344	1788	Grossmann V	The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.	Genes, chromosomes and cancer	2013	31
23603912	1788	Neumann M	Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.	Blood	2013	45
19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
20921461	1956	Roberts PJ	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	Journal of clinical oncology 	2010	77
20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
21258415	1956	Normant E	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene	2011	46
21277552	1956	Pao W	New driver mutations in non-small-cell lung cancer.	The Lancet. Oncology	2011	244
21303969	1956	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	87
21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
21791641	1956	Sasaki T	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.	Cancer research	2011	157
22135231	1956	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	55
22235099	1956	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	213
22277784	1956	Katayama R	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.	Science translational medicine	2012	268
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
23552377	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	124
23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
23562183	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	60
23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
24065147	1956	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	53
24199682	1956	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	23
24443522	1956	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	29
24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
24857124	1956	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	23
25311215	1956	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	42
25394791	1956	Crystal AS	Patient-derived models of acquired resistance can identify effective drug combinations for cancer.	Science	2014	120
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
25689095	1956	Kumarakulasinghe NB	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015	16
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26416997	1956	Cai W	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.	Journal of clinical oncology 	2015	21
26537995	1956	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	19
26777916	1956	Barlesi F	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	Lancet	2016	43
27718847	1956	Reck M	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	The New England journal of medicine	2016	147
9360930	2120	Lacronique V	A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.	Science	1997	164
15908956	2120	Castor A	Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.	Nature medicine	2005	67
18202291	2120	Hong D	Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.	Science	2008	94
20409752	2120	Moorman AV	Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.	The Lancet. Oncology	2010	58
22162831	2120	Van Vlierberghe P	ETV6 mutations in early immature human T cell leukemias.	The Journal of experimental medicine	2011	49
14532106	2146	Bracken AP	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.	The EMBO journal	2003	331
21078963	2146	Sneeringer CJ	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.	Proceedings of the National Academy of Sciences of the United States of America	2010	139
21367748	2146	Chase A	Aberrations of EZH2 in cancer.	Clinical cancer research 	2011	141
22323599	2146	McCabe MT	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).	Proceedings of the National Academy of Sciences of the United States of America	2012	101
24052547	2146	Bödör C	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	Blood	2013	30
25457180	2146	Bradley WD	EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.	Chemistry and biology	2014	31
20952518	2322	Borthakur G	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.	Haematologica	2011	45
22715121	2322	Iland HJ	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).	Blood	2012	34
23631653	2322	Kayser S	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.	Leukemia and lymphoma	2014	28
25253770	2322	Irving J	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	Blood	2014	39
20972433	3195	De Keersmaecker K	The TLX1 oncogene drives aneuploidy in T cell transformation.	Nature medicine	2010	51
2547513	3265	Bos JL	ras oncogenes in human cancer: a review.	Cancer research	1989	956
14564000	3561	Hacein-Bey-Abina S	LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.	Science	2003	831
21536738	3575	Shochat C	Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.	The Journal of experimental medicine	2011	89
21892159	3575	Zenatti PP	Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.	Nature genetics	2011	90
19470474	3716	Mullighan CG	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	148
23406773	3716	Quintás-Cardama A	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.	Clinical cancer research 	2013	59
15860661	3717	Steensma DP	The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.	Blood	2005	76
16325696	3717	Campbell PJ	Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.	Lancet	2005	83
18805579	3717	Bercovich D	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.	Lancet	2008	91
19965641	3717	Hertzberg L	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.	Blood	2010	85
22869151	3717	Vainchenker W	JAK/STAT signaling in hematological malignancies.	Oncogene	2013	63
25671252	3717	Ortmann CA	Effect of mutation order on myeloproliferative neoplasms.	The New England journal of medicine	2015	55
10395545	3981	Riballo E	Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient.	Current biology 	1999	96
9771704	4068	Coffey AJ	Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene.	Nature genetics	1998	106
21368758	4261	Steidl C	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.	Nature	2011	105
18538732	4297	Wei J	Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.	Cancer cell	2008	108
20016527	4297	Salzer WL	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.	Leukemia	2010	46
22017583	4297	Muntean AG	The pathogenesis of mixed-lineage leukemia.	Annual review of pathology	2012	73
25730765	4297	Andersson AK	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.	Nature genetics	2015	46
17435759	4602	Lahortiga I	Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.	Nature genetics	2007	75
17452517	4602	Clappier E	The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children.	Blood	2007	84
19841262	4602	Persson M	Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.	Proceedings of the National Academy of Sciences of the United States of America	2009	125
25394790	4602	Mansour MR	Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.	Science	2014	104
6414718	4609	Battey J	The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.	Cell	1983	212
10713166	4609	Gregory MA	c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.	Molecular and cellular biology	2000	117
11607812	4609	Boxer LM	Translocations involving c-myc and c-myc function.	Oncogene	2001	95
12808131	4609	Li Z	A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	192
12808455	4609	Roix JJ	Spatial proximity of translocation-prone gene loci in human lymphomas.	Nature genetics	2003	105
16094360	4609	Hemann MT	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	Nature	2005	152
16760443	4609	Dave SS	Molecular diagnosis of Burkitt's lymphoma.	The New England journal of medicine	2006	179
17646408	4609	Thompson BJ	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	The Journal of experimental medicine	2007	147
19597184	4609	Johnson NA	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	Blood	2009	73
20498406	4609	Barrans S	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.	Journal of clinical oncology 	2010	71
22002575	4609	Li S	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	Modern pathology 	2012	34
22851565	4609	Johnson NA	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	96
23001146	4609	Calado DP	The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.	Nature immunology	2012	53
23352430	4609	Barlow JH	Identification of early replicating fragile sites that contribute to genome instability.	Cell	2013	80
21179087	4615	Ngo VN	Oncogenically active MYD88 mutations in human lymphoma.	Nature	2011	264
22837180	4615	Gonzalez-Aguilar A	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.	Clinical cancer research 	2012	38
22931316	4615	Treon SP	MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.	The New England journal of medicine	2012	116
23321251	4615	Xu L	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.	Blood	2013	39
19412164	4790	Compagno M	Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.	Nature	2009	297
1831692	4851	Ellisen LW	TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.	Cell	1991	380
15472075	4851	Weng AP	Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.	Science	2004	749
16738328	4851	Malecki MJ	Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.	Molecular and cellular biology	2006	88
17575125	4851	Malyukova A	The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.	Cancer research	2007	57
20008221	4851	Ferrando AA	The role of NOTCH1 signaling in T-ALL.	Hematology. American Society of Hematology. Education Program	2009	51
22006338	4851	Wang NJ	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	108
22210878	4851	Kridel R	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.	Blood	2012	52
23295735	4851	Villamor N	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.	Leukemia	2013	26
23825651	4851	Kluk MJ	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.	PloS one	2013	28
25194570	4851	Herranz D	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.	Nature medicine	2014	45
22891273	4853	Rossi D	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.	The Journal of experimental medicine	2012	61
22891276	4853	Kiel MJ	Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.	The Journal of experimental medicine	2012	46
17344859	5079	Mullighan CG	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.	Nature	2007	467
17951530	6774	Ding BB	Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.	Blood	2008	78
21205967	7157	Fabbri M	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	JAMA	2011	72
21747090	7157	Hof J	Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.	Journal of clinical oncology 	2011	41
22955915	7157	Xu-Monette ZY	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	Blood	2012	42
22965953	7157	Lehmann S	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	Journal of clinical oncology 	2012	58
22897847	10019	Roberts KG	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.	Cancer cell	2012	141
25207766	10019	Roberts KG	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	The New England journal of medicine	2014	142
18768390	10320	Yang JJ	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.	Blood	2008	55
19129520	10320	Mullighan CG	Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.	The New England journal of medicine	2009	274
19589926	10320	Iacobucci I	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).	Blood	2009	50
19770381	10320	Martinelli G	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.	Journal of clinical oncology 	2009	61
20139093	10320	Harvey RC	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.	Blood	2010	112
20445578	10320	Kuiper RP	IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.	Leukemia	2010	57
22368272	10320	Chen IM	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.	Blood	2012	59
23212523	10320	Loh ML	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.	Blood	2013	32
24366361	10320	van der Veer A	IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.	Blood	2014	25
24740809	10320	Beldjord K	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.	Blood	2014	23
26321221	10320	Churchman ML	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.	Cancer cell	2015	19
17512414	10664	Barski A	High-resolution profiling of histone methylations in the human genome.	Cell	2007	2338
11090634	10892	Uren AG	Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma.	Molecular cell	2000	190
27030389	29126	Georgiou K	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.	Blood	2016	11
27069084	29126	Roemer MG	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	Journal of clinical oncology 	2016	25
27269947	29126	Lesokhin AM	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	Journal of clinical oncology 	2016	35
22366949	30012	Della Gatta G	Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.	Nature medicine	2012	45
20660823	54474	Thomas DA	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.	Journal of clinical oncology 	2010	47
22760778	54790	Lemonnier F	Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.	Blood	2012	55
23831920	54790	Asmar F	Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.	Haematologica	2013	27
19838194	64109	Mullighan CG	Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.	Nature genetics	2009	140
19124805	80150	Huguet F	Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.	Journal of clinical oncology 	2009	63
19776401	81704	Zhang Q	Combined immunodeficiency associated with DOCK8 mutations.	The New England journal of medicine	2009	135
18323416	84433	Lenz G	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.	Science	2008	216
25326804	171023	Xie M	Age-related mutations associated with clonal hematopoietic expansion and malignancies.	Nature medicine	2014	168
22343534	100271849	Lohr JG	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2012	240
23292937	100271849	Zhang J	Genetic heterogeneity of diffuse large B-cell lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2013	108
24145436	100271849	Beà S	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2013	67
26256760	100271849	Pastore A	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	The Lancet. Oncology	2015	24
